Literature DB >> 8253519

Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model.

M A Shibata1, R Hasegawa, T Shirai, Y Takesada, S Fukushima.   

Abstract

The chemopreventive effects of indomethacin (IM) on the enhancement of bladder carcinogenesis and transitional-epithelial-cell proliferation by butylated hydroxyanisole (BHA) or sodium L-ascorbate (Na-AsA) were investigated. All animals were given 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for 4 weeks. They then received 2% BHA or 5% Na-AsA for 20 weeks, followed by 20 ppm IM in the drinking water or normal tap water without supplement for a further 20 weeks, or BHA or Na-AsA alone or concomitantly with IM for 40 weeks. No differences in bladder-tumor development were found when IM was administered after cessation of BHA or Na-AsA exposure. However, IM in combination with either BHA or Na-AsA significantly reduced both the incidence and the multiplicity of papillomas and carcinomas as compared with the values of groups receiving BHA or Na-AsA alone. This was associated with decreased DNA synthesis and prostaglandin (PG) E2 levels in the existing bladder tumors. Combined treatment with IM did not exert any effects on BHA forestomach carcinogenesis. A separate 8-week combination study demonstrated that IM diminished the increase in expression of proliferation nuclear-cell antigen (PCNA) induced by BHA or Na-AsA alone. The present results suggest that PGE2 may be involved in promotion of rat bladder carcinogenesis and that the PG synthesis blocker IM might exert preventive effects on the development of bladder cancer in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253519     DOI: 10.1002/ijc.2910550622

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

2.  Non-steroidal anti-inflammatory drugs and bladder cancer prevention.

Authors:  J E Castelao; J M Yuan; M Gago-Dominguez; M C Yu; R K Ross
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

3.  Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.

Authors:  Hirokazu Tachibana; Min Gi; Minoru Kato; Shotaro Yamano; Masaki Fujioka; Anna Kakehashi; Yukiyoshi Hirayama; Yuki Koyama; Satoshi Tamada; Tatsuya Nakatani; Hideki Wanibuchi
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

4.  Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma.

Authors:  Mitsuru Futakuchi; Kumiko Ogawa; Masashi Sano; Seiko Tamano; Fumitaka Takeshita; Tomoyuki Shirai
Journal:  Jpn J Cancer Res       Date:  2002-10

5.  Decrease of prostaglandin E2 and 5-bromo-2'-deoxyuridine labeling but not prostate tumor development by indomethacin treatment of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate.

Authors:  M Kawabe; M A Shibata; M Sano; Y Takesada; S Tamano; N Ito; T Shirai
Journal:  Jpn J Cancer Res       Date:  1997-04

6.  Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment.

Authors:  E Okajima; S Ozono; T Endo; T Majima; M Tsutsumi; T Fukuda; H Akai; A Denda; Y Hirao; E Okajima; H Nishino; Z Nir; Y Konishi
Journal:  Jpn J Cancer Res       Date:  1997-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.